The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide.

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Salk Institute scientists are looking for a new treatment strategy in microproteins, an understudied class of molecules found ...

Researchers developed a method to dissect immune-regulatory programs via integrative time-series analysis and high-content CRISPR screening.

Mars, maker of M&M's and Skittles, is turning to CRISPR gene editing to develop more resilient cacao plants, with the aim of ...

CRISPR gene editing shows potential for treating genetic diseases. Explore how it may impact Down syndrome treatment and ...

By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a ...

The multiagent AI system, dubbed “CRISPR-GPT,” is designed to interact and reason with human users as they execute ...

CRISPR Therapeutics, trading under, operates within the biotechnology sector, a key area of interest within the broader ...

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.

SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic ...